

NDA 201848/S-003

SUPPLEMENT APPROVAL

Delcath Systems, Inc. Attention: Ashleigh Lamson Director, Regulatory Affairs 566 Queensbury Avenue Queensbury, NY 12804

Dear Ashleigh Lamson:

Please refer to your supplemental New Drug Application (sNDA) dated and received November 27, 2023, and your amendment, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for HEPZATO KIT[™] (melphalan) for Injection/Hepatic Delivery System.

This "Changes Being Effected" supplemental new drug application provides for the final printed labeling as agreed upon by the Agency at the time of NDA approval and included in the NDA Approval letter dated August 14, 2023.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(I)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (instructions for use) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/GuidanceS/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

NDA 201848/S-003 Page 2

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELS

Submit final printed carton and container labels that are identical to enclosed carton and container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission "**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 201848/S-003.**" Approval of this submission by FDA is not required before the labeling is used.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

U.S. Food & Drug Administration Silver Spring, MD 20993 www.fda.gov NDA 201848/S-003 Page 3


If you have any questions, please contact Janell Artis, PharmD., Regulatory Business Process Manager at email: <u>Janell.Artis@fda.hhs.gov</u>, or (301) 796 – 6309.

Sincerely,

{See appended electronic signature page}

Ramesh Raghavachari, Ph.D. Supervisor Division of Product Quality Assessment IV Office of Product Quality Assessment I Office of Pharmaceutical Quality Center for Drug Evaluation and Research

Enclosure(s): Content of Labeling Carton and Container Labeling



Digitally signed by Ramesh Raghavachari Date: 5/22/2024 05:34:32PM GUID: 502d0913000029f375128b0de8c50020